Patient death prompts pause in 2seventy bio's cancer therapy study.
Originally Published 2 years ago — by Endpoints News
Seattle Children's has paused a Phase I study of 2seventy bio's CAR-T cell therapy, SC-DARIC33, following the death of a patient who received the therapy at the second dose level. The therapy is being investigated in pediatric and young adult patients with acute myeloid leukemia, and the cause of the adverse event is currently under investigation.